Trial of Stentys self-apposing stent (Stentys) demonstrates low mortality rates in CAD patients

One-year results of the APPOSITION III clinical trial in 1000 CAD patients post treatment of a severe heart attack show that the Stentys Self-Apposing Stent, from Stentys, demonstrates low mortality rates in patients. The APPOSITION III trial is a prospective single-arm multi-center study designed to assess the long term performance of Stentys Self-Apposing Stents in routine clinical practice in Europe among patients suffering from ST-elevation myocardial infarction (STEMI).

The primary endpoint Major Adverse Cardiac Events rate at one year was 9.3% where conventional stents average 11.1% in a pooled analysis from ACTION Study Group. At the one-year time point the cardiac death rate was 2.0% as compared with rates for conventional stents in other published trials which average 3.9% the lowest rate being 2.2%. The low rates of mortality (2.0%) and target-vessel re-infarction (1.3%) in the APPOSITION III study highlight the safety profile of Self-Apposing stents. Data was presented at the American College of Cardiology�s Scientific Session.